Current follow-up results: 8/30 (26.7%) patients died, average 9.0 ± 4.3 months, pathologic types (non-keratinizing carcinoma; Skeletal muscle sarcoma, bone sarcoma, embryonic rhabdomyosarcoma, chondrosarcoma, scleroderma sarcoma, high-grade epidermal carcinoma. Tumor progression, recurrence: 6/30 (20%), average 9.0 ± 4.3 months, pathologic types (Hemangiopericytome malin grade III, Sarcoma (skeletal muscle, bone, embryonic rhabdomyosarcoma, scleroderma), non - keratinizing carcinoma).